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Abstract
Objective: Inflammation of the immune system and the central nervous system has been known as an important predisposing 
factor for Parkinson’s disease (PD). Increased expression of OX40 protein (CD134) is a known factor for increased inflammation 
and initiation of NF-kappa-B signaling pathway in different diseases. We aimed to investigate the expression of OX40 at the 
transcript and serum protein levels.  
Materials and Methods: Twenty individuals with PD and 20 healthy individuals, as controls, were enrolled in this case-
control study. Expression of OX40 at the transcript level and serum protein levels were measured by quantitative real-time 
polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assays respectively.  
Results: The mean expression level of OX40 was increased in patients but not at a significant level (P>0.05). 
Consistently, the mean serum concentration of OX40 showed a mild, but non-significant, increase in the patients 
(P>0.05).                    
Conclusion: We conclude that OX40 expression at either the transcript or protein level has no diagnostic utility in 
asymptomatic PD. This shows the need for clinical, cellular and interventional research to detect new robust biomarkers. 
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Introduction
Parkinson’s disease (PD) is the second leading 
neurodegenerative disease after Alzheimer’s disease, 
which causes symptoms such as slowness of movement 
or vibration in the hands and other limbs (1). PD 
mainly affects the central nervous system (CNS) and 
consequently the motor system. This disease generally 
begins with death and reduction of dopaminergic neurons 
in substantia nigra and progresses with the accumulation 
of Lewy bodies, comprising alpha-synuclein and 
ubiquitin (2). Tremor of hands, muscle stiffness in 
movement and slow movements during walking are 
some of the early clinical symptoms of PD. Following 
the incidence of early symptoms and the progression of 
the disease, behavioral and emotional problems become 
more apparent including dementia, depression, sleep 
problems and intellectual disability (3). 
Several studies have led to the identification of 
a number of genes implicated in PD pathogenesis 
and have therefore, to some extent, shed light on 
the pathogenic mechanisms of this disease. Alpha-
synuclein (autosomal dominant), Lewy body-positive 
PARK1 and PARKIN (autosomal recessive), juvenile 
PARK2 and Lewy body-negative are some of these 
genes (4, 5). In addition, many studies have been 
conducted at the protein level, profiling cells involved 
in PD. These studies have indicated that the expression 
rate of proteins in different molecular pathways 
including glycolysis, tricarboxylic acid, apoptotic 
pathways, and cell viability as well as cytoskeleton-
related proteins change significantly, thus being 
associated with the pathogenesis of PD (6, 7). 
The interaction effect between inflammation and 
neuron dysfunction is complicated and the causes of 
PD have not yet been elucidated. However, there is 
ample evidence for dysfunction and inflammation of 
the immune system and CNS as important predisposing 
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factors for the development of PD (8, 9). Activation of 
necroptosis pathways in neurons may cause activation 
of immune-inflammatory pathways and by producing 
neurotoxic cytokines may lead to neuronal death (10). 
Suppression of inflammation responses in innate and 
acquired immunity and changes in the expression 
rate of proteins involved in this process, as a basis 
for a highly efficient treatment, have attracted much 
attention in the recent years. 
A key gene involved in immune-inflammatory 
pathways, OX40, encodes the protein OX40 (Kd50), 
also known as CD134 and TNFRSF4 and functionally 
known as a tumor necrosis factor receptor. This 
receptor helps activate the NF-kappa-B pathway 
through binding to the adaptor proteins TRAF2 and 
TRAF5 (11). Moreover, activation of T cells, using 
CD134L-expressing cells, results in clonal expansion, 
and production and secretion of cytokines. There is 
evidence showing that OX40 plays a part in inducing 
T cell responses in autoimmune diseases, and blocking 
OX40 signaling may be considered as a treatment 
approach for many autoimmune diseases. 
The direct correlation between OX40 protein level 
in peripheral blood, and severity and progression of 
autoimmune diseases has been studied (12-14). Changes 
in OX40 protein expression has also been investigated 
in certain diseases such as atherosclerosis, rheumatoid 
arthritis, and inflammatory diseases of bowel and 
muscle (15-17). Moreover, the effect of suppressing 
the interaction between OX40 and its receptor has 
been investigated for the treatment of many diseases 
including asthma and allergy, atherosclerosis, diabetes, 
and systemic lupus erythematosus (SLE) (18-20). 
Given that the OX40 expression level in the peripheral 
blood of people with PD may provide insight into the 
immunologic mechanisms related to PD progression, 
we aimed to examine the association of OX40 
expression with PD for potential diagnosis of PD and 
to develop more effective treatment approaches.  
Materials and Methods
In this case-control study, patients with PD who were 
referred to Kashani Hospital of Isfahan volunteered to 
participate were enrolled if diagnosis of PD was confirmed 
by magnetic resonance imaging (MRI) or by a specialist 
according to the clinical symptoms including tremors 
or shaking, stiffness and muscle pain, limited and slow 
movements, pain and balance disorders (UK Parkinson’s 
Disease Society Brain Bank Clinical Diagnostic Criteria) 
(21). Before enrollment, adequate explanations were 
given to the individuals, and written informed consent 
were obtained. The demographic characteristics of 
each individual were also obtained by the means of a 
questionnaire. This study was approved by the Ethics 
Committee of the Isfahan University of Medical Sciences 
(ref: IR.MUI.REC.1395.3.173). 
The exclusion criteria for selecting healthy controls 
were suffering from any autoimmune disease, 
previous organ transplantation and suffering from 
any inflammatory disease according to the results of 
erythrocyte sedimentation rate and C-reactive protein, and 
multiple sclerosis. The number of patients and controls 
were set according to a study analyzing the expression 
rate of OX40 (22) and according to the sample calculation 
formula by assuming 20%  overexpression in patients, 
95% confidence interval (CI) and 80% power, a total of 
20 individuals were analyzed in each group. The groups 
were matched by demographic characteristics (i.e. age 
and sex). 
A total of 5 ml venous blood was taken from 
each individual by observing safety and health 
recommendations, of which 2 ml was collected in EDTA-
containing tubes to extract RNA. The other 3 ml of blood 
was kept in a distinct tube without any anti-coagulant for 
serum analysis.
 
ELISA
The blood samples collected for serum analysis were 
centrifuged at 4000 rpm for 6 minutes to isolate the 
serum. One hundred microliter of the serum sample 
was poured into a separate tube and stored in a freezer 
at -20˚C. To measure the level of serum OX40, human 
sCD134 (OX40) Platinum ELISA-eBioscience was 
used and standard curve was drawn using the derived 
values based on data from the ELISA reader (Hiperion, 
Germany). Optical density (OD) at 450 nm wavelength 
was recorded in the samples of the two groups. The 
mean OD was 0.061 and 0.057 nm in the patient and 
control groups respectively.  
 OX40 gene expression
Total RNA was extracted using the YTA Total 
Purification mini kit for blood (Qiagen, China) according 
to the standard protocol. cDNA was synthesized with the 
Revertaid First cDNA synthesis kit (Fermentase, United 
States). 
Primers specific to OX40 and GAPDH, a housekeeping 
gene as the internal control, were designed using the 
Allele ID software and BLAST (NCBI online server). 
The details of the primers were:
OX40-
F: 5´TGGTGTAACCTCAGAAGTG3´
R: 5´GTCAACTCCAGGCTTGTA3´
GAPDH-
F: 5´CTCCCGCTTCGCTCTCTG3´
R: 5´TCCGTTGACTCCGACCTTC3ˊ
In each qPCR reaction, run on a Rotor-gene 6000 
(Corbett Life Science, Australia), a 10 µl mixture 
consisting of 6.25 ml SYBR Green Master Mix 
(Applied Biosystems, UK), 0.5 ml (5 pmol) of each 
primer, 1.75 ml nuclease free water and 1 ml (5 ng) 
genomic DNA. The reactions of each cDNA sample 
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were simultaneously conducted in triplicate for each 
pair of genes and the mean Ct was calculated for 
each gene. The cycling conditions were an initial 
denaturation at 95˚C for 5 minutes, followed by 40 
cycles of 95˚C for 15 seconds, 60˚C for 20 seconds, 
and 72˚C for 25 seconds. 
To investigate the outcome of amplification reactions 
of both genes, standard dilutions (50-3.13 ng/microL) 
of cDNA of each gene were prepared. After qPCR, 
the standard curve was drawn for each PCR fragment. 
PCR efficiency was calculated by determining the 
slope of the standard curve and using the formula 
efficiency=[10-1/slope]. Relative expression was calculated 
according to Schmittgen and Livak (23). 
To ensure that RNA concentration is equal in different 
reactions, GAPDH was used as internal control. For 
each sample, real-time PCR was conducted for OX40 
and GAPDH in triplicate under similar conditions, and 
a sample without cDNA considered negative control. 
For all reactions, melting curves were analyzed to 
ensure the specificity of the PCR product of interest.
Statistical analysis
In this study, statistical analyses were performed 
using the Statistical Package for the Social Sciences 
(SPSS, IBM corporation) software version 19. The 
Shapiro-Wilk test was used to investigate normality 
of the data. The data were then analyzed by a non-
parametric test, i.e. the Mann-Whitney U test. For all 
comparisons, P<0.05 was considered as statistically 
significant.
 Results
Patients
The patient group consisted of fifteen males and five 
females. The mean age of the patient group was 67 (range 
of 46-88) years. Demographic characteristics of the of 
the two groups of patients and controls, and baseline 
characteristics, based on the PD Questionnaire-39 have 
listed below (Tables 1, 2). The distribution of age and 
gender in the two groups was not significantly different 
(P>0.05).
Table 1: Distribution of demographic characteristics in both study 
groups
P valueSexP valueMean ± SDGroup
FemaleMale
Age (Y)
0.6425150.80569.05 ± 9.43  Control
51569.80 ±  9.66  Patient
Table 2: The baseline characteristics of patients
Characteristics of patients Mean ± SD
n=18 
 Age of onset (Y)  65.78 ± 11.72
 Disease duration  4.11 ± 3.36
 PDQ-39
    D1  55.28 ± 30.29
    D2  41.20 ± 27.37
    D3  42.13 ± 33.15
    D4  47.57 ± 43.73
    D5  19.21 ± 10.31
    D6  37.50 ± 27.87
    D7  36.57 ± 33.60
    D8  60.64 ± 23.88
    Total (PDSI)  42.51 ± 20.43
 Family history,  n (%)
   Yes  5 (27.8)
   No  13 (72.2)
PDQ; Parkinson’s Disease Questionnaire, PDSI; Parkinson’s disease 
symptom inventory, and D; Discrete scale.
ELISA
According to the standard curve and OD of the studied 
samples, OX40 concentration of the participants was 
calculated. The mean serum concentration of OX40 
protein was 13.65 pg/ml in the patients and 10.67 pg/ml 
in the controls. Given that this variable was not normally 
distributed in the two groups (P<0.05), the Mann-Whitney 
U test was used to compare the independent groups. 
Although the mean concentration was higher in the patient 
group, the difference was not significant (P=0.144, Fig.1).
Fig.1: The mean serum concentration of OX40 in the patient and control 
groups. 
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Real-time polymerase chain reaction
Quantity and quality of extracted RNA
Concentration of RNA at the 260 nm and 280 nm 
wavelengths was calculated and its ratio (260/280) was 
between 1.8 to 2. The quality of RNA extracted was 
examined by agaroz gel electrophoresis.
 OX40 expression analysis
As shown in Figure 2, the mean relative expression of 
OX40 was 4.89 and 4.23 in the patient and control groups. 
Because the studied variable was not normally distributed in 
the two groups (P<0.05), the Mann-Whitney U test of two 
independent samples was used. Although OX40 expression 
was increased in the patient group, the difference was not 
statistically significant (P=0.433, Fig.2). 
Fig.2: The relative expression of OX40 in peripheral blood of the patient 
and control groups. 
 The relationship of OX40 transcript and protein
expression levels with gender
We observed no significant difference in OX40 transcript 
and protein expression between men and women of the 
patient group (P>0.05). Gender-specific expression values 
are listed below (Table 3).
Table 3: Comparison of OX40 transcript and protein expression between 
males and females in the patient group
Mean ± SD
n=15
P value
OX40 Gene
   Male 5.33 ± 1.91 0.434
   Female 2.49 ± 2.01
Concentration of OX40 protein
    Male 14.73 ± 2.90  0.435
    Female 10.42 ± 3.06
 The relationship of OX40 transcript and protein
expression levels with age.
Results showed no correlation between age and OX40 
expression (P=0.506, r=0.158). Similarly, no correlation 
was found at the protein level (P=0.229, r=0.282).
 Correlation between transcript and protein levels of
OX40
We observed a significant correlation between the 
transcript and protein levels of OX40 expression (P=0.001, 
r=0.888, Fig.3).
Fig.3. Scatter plot of patients based on their OX40 expression at the 
transcript (y-axis) and protein (x-axis) levels. Expression at the two levels 
were significantly correlated (P=0.001).
Discussion
PD is a common disease of CNS and the motor system 
with underlying genetic, epigenetic, and environmental 
factors. Monogenic disorders and mutations in certain 
genes such as LRRK2, PINK1 and PARKIN may cause 
PD with different levels of penetrance depending on 
the genotype of the individual (24). However, there 
are other genes that may cause dopaminergic neuron 
damage due to certain changes such as fighting oxidative 
stress, apolipoprotein E  (APOE), glucocerebrosidase, 
monoamine oxidase and microtubule-associated protein 
tao  (MAPT), and therefore increase predisposition to 
develop PD (25).
In recent years, the role of other proteins in 
increasing predisposition to PD has been investigated, 
including genes involved in inflammatory processes 
and mechanisms of acquired and innate immunity. 
For instance, the association between inflammation of 
peripheral neuritis and nerve damage in patients with 
PD has been reported based on clinical evidence. Su and 
Federoff (26) demonstrated that systemic inflammation in 
PD patients included increased serum levels of TNF-α and 
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its receptor as well as interlukin-6 (IL-6) compared with 
the controls. CD134 (OX40 protein) is a tumor necrosis 
factor receptor family. Its ligand, OX40L (CD134L), is a 
member of the TNF family and is expressed on activated 
T cells, B cells, dendritic cells, macrophages, endothelial 
cells and microglia. The OX40-OX40L interaction plays 
a key role in function and viability of activated T cells and 
production of T memory cells (27, 28). 
We observed no significant change in OX40 expression 
at either the transcript or protein level. However, it 
is necessary to conduct comprehensive genetic and 
epigenetic studies to explain the genetic factors in complex 
diseases such as PD. Different genetic risk factors for PD 
have been investigated. Few of the genetic factors are 
transferred in a monogenic Mendelian fashion such as the 
autosomal dominant mutations in genes encoding alpha-
synuclein (SNCA), Leucine-rich repeat kinase 2, and 
VPS35, and autosomal recessive mutations in PINK1/
PARKIN/DJ-1, glucocerebrosidase, PLA2G6, FBX07 
and ATP13A2 (29). In addition, the role of defective 
mitochondrial function in PD due to mutations in the 
nuclear and mitochondrial genomes has been frequently 
investigated (30).
Medical knowledge about the genetic predisposition to 
certain diseases such as PD has grown remarkably in the 
recent decades. In fact, detecting clinical characteristics 
of monogenic types of PD has resulted in identifying 
defective pathways in its pathogenesis including 
defective mitochondrial function, new signaling pathways 
and protein metabolism. In contrast, study of large 
populations indicates that variants with lower risk have 
a 30% contribution to heritability of PD sporadic types 
due to high frequency. The remaining contribution to PD 
heritability depends on genes with more balanced risk 
and more recent mechanisms such as somatic mutations 
and epigenetic effects (31). It is, however, not still 
possible to predict the incidence of this disease in people, 
which represents the genetic complexity of this disease. 
Accordingly, the expression rate of a single gene and the 
serum level of its protein could not influenced by of the 
interactions.
 We suggest that the lack of association in this study may 
be due to sample size or blood cells may not be a suitable 
representative for the CNS. In contrast to the present 
study, some studies indicate increased OX40 protein and 
its ligand on T cells surface helps launch inflammatory 
pathways of necrosis and apoptosis (28). Understanding 
the exact etiology of a disease depends on the careful 
study of its phenotype. 
PD is diagnosed with clinical conditions, including 
asymmetrical movements, slow movements, and the 
response to dopamine therapy. Given the differences 
that are manifested in the PD phenotype spectrum, the 
genotype-phenotype correlation is highly complex. 
Except a few cases of monogenic Mendelian inheritance 
patterns, polygenic predisposition to PD is likely to be 
the genetic basis of most patients and has thus been much 
frequently investigated (32). For instance, Mendelian 
inheritance is not observed in patient generations (33) and 
even identical twins show disconcordance (34, 35). 
Moreover, epigenetic factors can be effective on the 
expression profile of the genes as well as incidence of 
different phenotypes. Information on epigenetic factors 
is still limited but studies on this area will probably help 
explain how certain diseases such as PD are inherited. 
Epigenetics make it possible to control certain processes 
such as methylation, phosphorylation, acetylation, and 
production of gene expression-regulating microRNAs 
in the presence of a specific stimulus. For example, 
according to recent studies, methylation in substantia 
nigra in people with sporadic PD can decrease SNCA 
expression (36, 37). In addition, the expression patterns of 
different microRNAs can lead to defective mitochondrial 
function in people with PD (38). 
It is therefore likely that in the patient group analyzed 
here, the interactions among various genes as well as 
different environmental and epigenetic factors may have 
led to change in the expression profile of the studied gene. 
It can therefore be argued that the expression of a specific 
gene that is hypothetically associated with the incidence 
of a disease may be influenced by different regulatory 
pathways and environmental conditions as well as the 
expression of other genes.  
Conclusion
We conclude that given the lack of significant expression 
change of OX40 in blood samples of PD patients, 
measuring the expression of this gene in blood is unlikely 
to be a biomarker for PD diagnosis. Additional clinical, 
cellular and interventional studies are therefore needed to 
assess its expression directly in the CNS and also develop 
novel biomarkers.
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